Levy, M. Y., Stein, A. S., Vasu, S., Maris, M. B., Advani, A. S., Fathi, A. T., … Erba, H. (2017). A PHASE 1B STUDY OF THE COMBINATION OF VADASTUXIMAB TALIRINE AND 7+3 INDUCTION THERAPY FOR PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA. In HAEMATOLOGICA (Vol. 102, pp. 324–324). Madrid, SPAIN: FERRATA STORTI FOUNDATION.

Levy, M. Y., A. S. Stein, S. Vasu, M. B. Maris, A. S. Advani, A. T. Fathi, S. Faderl, et al. “A PHASE 1B STUDY OF THE COMBINATION OF VADASTUXIMAB TALIRINE AND 7+3 INDUCTION THERAPY FOR PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA.” In HAEMATOLOGICA, 102:324–324. FERRATA STORTI FOUNDATION, 2017.

Levy MY, Stein AS, Vasu S, Maris MB, Advani AS, Fathi AT, et al. A PHASE 1B STUDY OF THE COMBINATION OF VADASTUXIMAB TALIRINE AND 7+3 INDUCTION THERAPY FOR PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA. In: HAEMATOLOGICA. FERRATA STORTI FOUNDATION; 2017. p. 324–324.

Levy, M. Y., et al. “A PHASE 1B STUDY OF THE COMBINATION OF VADASTUXIMAB TALIRINE AND 7+3 INDUCTION THERAPY FOR PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA.” HAEMATOLOGICA, vol. 102, FERRATA STORTI FOUNDATION, 2017, pp. 324–324.

Levy MY, Stein AS, Vasu S, Maris MB, Advani AS, Fathi AT, Faderl S, Walter RB, Smith SE, Yang J, Donnellan WB, Wood BL, Ravandi F, Feldman EJ, Voellinger JL, Erba H. A PHASE 1B STUDY OF THE COMBINATION OF VADASTUXIMAB TALIRINE AND 7+3 INDUCTION THERAPY FOR PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA. HAEMATOLOGICA. FERRATA STORTI FOUNDATION; 2017. p. 324–324.